Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cells may hold key to predicting kidney disease relapse

NCT ID NCT07702981

Knowledge-focused Sponsor: University Hospital, Ioannina Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study looks at immune cell patterns in people with three types of nephrotic syndrome—membranous nephropathy, minimal change disease, and focal segmental glomerulosclerosis. Researchers aim to see if certain immune cells can serve as biomarkers to track how well a patient responds to treatment or to predict when the disease might come back. Participants receive standard therapies (rituximab or corticosteroids) and are followed for remission, relapse, and other health events.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rituximab or corticosteroids (depending on disease type)
What this could lead to
If successful, this could identify immune cell patterns that help doctors predict which patients will respond to treatment or relapse.
What could go wrong
This is a small, observational study focused on biomarkers, not a treatment trial. The findings may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

40 people

The number who actually took part.

Started

Jun 2023

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with primary MN, MCD and primary FSGS

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with nephrotic syndrome and a biopsy-confirmed diagnosis of membranous nephropathy, primary focal segmental glomerulosclerosis, or minimal change disease. 2. Patients with membranous nephropathy and positive serum anti-PLA2R antibodies, in the absence of histological confirmation by renal biopsy. 3. Patients with a previously confirmed diagnosis of primary nephrotic syndrome who present with disease relapse requiring re-induction therapy. Exclusion Criteria: 1. Patients with nephrotic syndrome in whom membranous nephropathy, primary FSGS, or MCD has not been confirmed by renal biopsy (and who do not meet Inclusion Criterion 2). 2. Patients with secondary causes of nephrotic syndrome (malignancy, autoimmune disease, drug-induced, etc.). 3. Patients with active malignancy. 4. Patients with severe heart failure (NYHA class IV) or hepatic failure. 5. Patients with active infection or inflammation. 6. Patients receiving, or who received within the preceding 6 months, immunomodulatory agents for an unrelated condition.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Focal segmental glomerulosclerosis (FSGS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

focal segmental glomerulosclerosis lipoid nephrosis macular corneal dystrophy membranous glomerulonephritis nephrotic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Focal segmental glomerulosclerosis (FSGS) Membranous nephropathy Minimal change disease (MCD)

Contacts and locations

Locations

  • University Hospital of Ioannina

    Ioannina, Epirus, 45500, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.